| Bioactivity | ALX-1393, a selective GlyT2 inhibitor, has an antinociceptive effect on thermal, mechanical, and chemical stimulations in a rat acute pain model[1]. |
| In Vivo | ALX1393 (i.c.v.; 25, 50, and 100 μg) in normal rats suppresses the late-phase response in the formalin test but does not affect motor performance. ALX1393 inhibits mechanical and cold hyperalgesia in a dose-dependent manner[2]. |
| Name | ALX-1393 |
| CAS | 949164-09-4 |
| Formula | C23H22FNO4 |
| Molar Mass | 395.42 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Haranishi Y, et al. The antinociceptive effect of intrathecal administration of glycine transporter-2 inhibitor ALX1393 in a rat acute pain model. Anesth Analg. 2010 Feb 1;110(2):615-21. [2]. Takahashi Y, et al. Antinociceptive effect of intracerebroventricular administration of glycine transporter-2 inhibitor ALX1393 in rat models of inflammatory and neuropathic pain. Pharmacol Biochem Behav. 2015 Mar;130:46-52. |